Non Muscle Invasive Clinical Trials

38 recruitingLast updated: June 18, 2026

There are 38 actively recruiting non muscle invasive clinical trials across 22 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include San Antonio, Texas, United States, Dallas, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Non Muscle Invasive Trials at a Glance

38 actively recruiting trials for non muscle invasive are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in San Antonio, Dallas, and New York. Lead sponsors running non muscle invasive studies include Memorial Sloan Kettering Cancer Center, The First Affiliated Hospital with Nanjing Medical University, and BLATAM.

Browse non muscle invasive trials by phase

Treatments under study

About Non Muscle Invasive Clinical Trials

Looking for clinical trials for Non Muscle Invasive? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non Muscle Invasive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non Muscle Invasive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 1Phase 2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

Bladder CancerNon Muscle Invasive Bladder Cancer
Photocure500 enrolled4 locationsNCT07144319
Recruiting
Phase 2

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Non Muscle Invasive Bladder Cancer
BLATAM37 enrolled1 locationNCT06972615
Recruiting
Phase 1Phase 2

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

Bladder CancerUrothelial Carcinoma (UC)Muscle Invasive Bladder Cancer (MIBC)+1 more
Oslo University Hospital150 enrolled1 locationNCT07602010
Recruiting
Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled66 locationsNCT05951179
Recruiting
Phase 3

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center125 enrolled9 locationsNCT06929286
Recruiting
Phase 1

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center55 enrolled7 locationsNCT05126472
Recruiting
Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled9 locationsNCT05796375
Recruiting

AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Association Francaise d'Urologie8,000 enrolled44 locationsNCT05002556
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Non Muscle Invasive Bladder Cancer
Pfizer294 enrolled47 locationsNCT07206225
Recruiting
Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+3 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting
Phase 2

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled4 locationsNCT06503614
Recruiting

Effects of Microbiological and Immunological Factors on the Lower Urinary Tract

Non Muscle Invasive Bladder CancerChronic pelvic painAsymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying+5 more
University of Zurich800 enrolled1 locationNCT07494864
Recruiting
Not Applicable

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Istituto Oncologico Veneto IRCCS200 enrolled9 locationsNCT06245603
Recruiting
Phase 4

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Non Muscle Invasive Bladder CancerHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza327 enrolled1 locationNCT05962541
Recruiting
Phase 2

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
CHU de Quebec-Universite Laval160 enrolled7 locationsNCT05327647
Recruiting

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Non Muscle Invasive Bladder Cancer
Johns Hopkins University42 enrolled1 locationNCT05672615
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734